ACH Trial

ACH Trial

We are recruiting to a phase 2 study assessing the effects of a complement inhibitor on C3 glomerulopathy and immune-complex MPGN.

Study title: An Open-Label Phase 2 Proof-of-Concept Study in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated with ACH-0144471.

For further details contact: l.lightstone@imperial.ac.uk 

ACH Trial